Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia

समान संसाधन

• Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
  द्वारा: Sattar, N, और अन्य
  प्रकाशित: (2016)
• Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: Design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial
  द्वारा: Nissen, SE, और अन्य
  प्रकाशित: (2016)
• Effects of Long-term, Monthly Administration of the Pcsk9 Inhibitor Evolocumab (Amg 145) in Patients with Dysglycemia or Metabolic Syndrome
  द्वारा: Henry, R, और अन्य
  प्रकाशित: (2014)
• Lipid-modifying agents, from statins to PCSK9 inhibitors
  द्वारा: Preiss, D, और अन्य
  प्रकाशित: (2020)
• Pooled safety analysis of evolocumab in over 6000 patients from double-blind and open-label extension studies
  द्वारा: Toth, P, और अन्य
  प्रकाशित: (2017)